Nektar Therapeutics (NKTR)

Executive Summary

Nektar Therapeutics is a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for autoimmune and inflammatory diseases, leveraging its proprietary IL-2 pathway agonist technology to selectively expand regulatory T cells. The company has shifted its focus from oncology to autoimmune indications, with its lead candidate rezpegaldesleukin (REZPEG) advancing in Phase 2b trials for alopecia areata and atopic dermatitis. Nektar has a strong track record of partnerships, including collaborations with major pharmaceutical companies, and a pipeline that includes multiple clinical-stage assets. The company's valuation of ~$2 billion reflects investor optimism for its Treg-based platform, which aims to address root causes of immune dysregulation rather than symptoms. Key near-term milestones include Phase 2b data readouts for REZPEG in alopecia areata, expected in mid-2026, and potential partnering or licensing deals to expand its pipeline and financial runway.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b data readout for rezpegaldesleukin in alopecia areata55% success
• H2 2026Phase 2b data readout for rezpegaldesleukin in atopic dermatitis50% success
• 2026Potential partnership or licensing deal for REZPEG or other pipeline assets40% success